Jim Glasheen

Jim oversaw the founding of Atalanta in his former role as executive vice chancellor for innovation and business development at the University of Massachusetts Medical School. Prior to UMass, Jim was a venture capitalist for 20 years at Technology Partners and was an investor and/or board member in many companies including Cadence Pharmaceuticals (CADX: acquired by Mallinckrodt), Revance Therapeutics (RVNC), Iomai (IOMI: acquired by Intercell), Incline Therapeutics (acquired by the Medicines Company), Transcend Medical (acquired by Novartis), Vision 5 (acquired by Allergan), Corcept (CORT) and Elcelyx.

Jim is also the co-founder and co-chairman of ConsumerMed, a nonprofit organization focused on patient-centered health. Prior to his venture career, he was a consultant with McKinsey and Company and was a leader within their pharmaceuticals and medical products practice. He is a graduate of Duke University and Harvard University, where he received a Ph.D. in biology, and completed a postdoctoral fellowship at the University of California Berkeley.